Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00JDL
|
||||
| Former ID |
DIB010700
|
||||
| Drug Name |
MGD006
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Acute lymphoblastic leukemia; Acute myeloid lymphoma [ICD9: 204.0, 556; ICD10:C91.0, C92.0] | Phase 1 | [1], [2] | ||
| Company |
MacroGenics
|
||||
| Target and Pathway | |||||
| Target(s) | T-cell surface glycoprotein CD3 | Target Info | Modulator | [1] | |
| Interleukin 3 receptor | Target Info | Modulator | [1] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | |||||
| Apoptosis | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| NetPath Pathway | IL5 Signaling Pathway | ||||
| IL3 Signaling Pathway | |||||
| Pathway Interaction Database | IL3-mediated signaling events | ||||
| Reactome | GPVI-mediated activation cascade | ||||
| G beta:gamma signalling through PI3Kgamma | |||||
| Interleukin-3, 5 and GM-CSF signaling | |||||
| RAF/MAP kinase cascade | |||||
| Interleukin receptor SHC signaling | |||||
| WikiPathways | IL-3 Signaling Pathway | ||||
| Interleukin-2 signaling | |||||
| Interleukin-3, 5 and GM-CSF signaling | |||||
| References | |||||
| REF 1 | A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87. | ||||
| REF 2 | ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.